Esketamine: Postmarketing Safety Concerns
How risky is esketamine? In this episode, we examine the safety of esketamine using postmarketing data that have been reported since the drug was approved and released.
Faculty: Jim Phelps, M.D.
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.
- Learn more about Premium Memberships here
- Earn 0.5 CMEs: Quick Take Vol. 27
- Postmarketing Safety Concerns With Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
